Taxane-induced peripheral neuropathy and quality of life in breast cancer patients

Salehifar, Ebrahim; Janbabaei, Ghasem; Alipour, Abbas; Tabrizi, Nasim; Avan, Razieh

doi:10.1177/1078155219898511

Cited by 8 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present it is known that chemotherapy-induced neuropathy interferes with the quality of life and it is often accompanied by depressive symptoms and apathy and abandonment of leisure activities and physical activity [49,54,55]. It should be taken into account that the symptoms of neuropathy can last between two to eleven years after its diagnosis in more than half of the patients, where tingling and numbness affect 70% of the patients with chemotherapy-induced peripheral neuropathy [55] and those patients displaying higher neuropathy symptoms also showed a reduced quality of life after chemotherapy discontinuation as recently reported for taxanes in patients with breast cancer [56] and for oxaliplatin in colorectal cancer patients [57] or carboplatin/taxanes regimen in patients with gynecologic cancer survivors [58]. Regarding diabetic patients and chemotherapy-induced neuropathy in terms of health-related quality of life, the study by Visser et al by using the European Organization for Research and Treatment of Cancer quality of life questionnaire-chemotherapy-induced peripheral neuropathy (EORTC QLQ-CIPN20) evaluated the differences in neuropathic symptoms between colorectal cancer patients with and without diabetes.…”

Section: Discussionmentioning

confidence: 88%

Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review

2021

View full text Add to dashboard Cite

Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight articles fulfilled the criteria, and four more articles were retrieved from the references of the selected articles. The analysis of the studies covered the information about neuropathy recorded in 768 cancer patients with diabetes and 5247 control cases (non-diabetic patients). The drugs investigated are chemotherapy drugs with high potential to induce neuropathy, such as platinum derivatives and taxanes, which are currently the mainstay of treatment of various cancers. The predisposing effect of co-morbid diabetes on chemotherapy-induced peripheral neuropathy depends on the type of symptoms and drug used, but manifest at any drug regimen dosage, although greater neuropathic signs are also observed at higher dosages in diabetic patients. The deleterious effects of chemotherapy on diabetic patients seem to last longer, since peripheral neuropathy persisted in a higher proportion of diabetic patients than non-diabetic patients for up to two years after treatment. Future studies investigating the risk of developing peripheral neuropathy in cancer patients with comorbid diabetes need to consider the duration of diabetes, cancer-induced neuropathic effects per se (prior chemotherapy administration), and the effects of previous cancer management strategies such as radiotherapy and surgery.

show abstract

Section: Discussionmentioning

confidence: 88%

Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review

2021

View full text Add to dashboard Cite

show abstract

“…In our study, the vast majority (82.7%) experienced taxane-related toxicities, with peripheral neuropathy being the most common, affecting 44.7% of patients receiving docetaxel and 56% among those receiving paclitaxel. In a study conducted in Iran, out of 346 breast cancer patients undergoing taxane chemotherapy, 23.7% developed peripheral neuropathy, and significant negative correlations were observed between overall health status/quality of life, physical functioning, and role performance with the degree of neuropathy experienced [29].…”

Section: Discussionmentioning

confidence: 99%

Breast Cancer: Clinical–Epidemiological Profile and Toxicities of Women Receiving Treatment with Taxanes in the Amazon Region

Costa,

Fernandes,

Pereira

et al. 2023

JPM

View full text Add to dashboard Cite

Breast cancer is the most common malignant disease and the leading cause of mortality among women worldwide. Antineoplastic chemotherapy is one of its primary treatments, typically based on the class of drugs known as taxanes. Despite their proven therapeutic efficacy, these drugs can induce severe toxicities, leading to dose limitations or even treatment discontinuation. The objective of this study was to describe the clinical–epidemiological profile, risk factors, and toxicities of taxane-based chemotherapy treatment in women with breast cancer in the Amazon region. This is a cross-sectional, quantitative, and descriptive study conducted with 300 women diagnosed with breast cancer undergoing taxane treatment. Most patients were in the 40–49 age range, of brown ethnicity, and had completed elementary school. The majority of patients had risk factors such as alcoholism and a sedentary lifestyles. Most women had their first pregnancy between the ages of 18 and 21, breastfed their children, had menarche between the ages of 12 and 13, and were pre-menopausal and with a family history of cancer. The most frequent histological type was non-special invasive carcinoma and the Luminal B subtype. Most participants in this study showed taxane toxicity, with neurotoxicity being the most frequent. These findings reveal the importance of early detection, comprehensive risk factors, and effective management of treatment toxicities to improve patient outcomes in breast cancer care in the Amazon region.

show abstract

“…Although they excluded participants whose main pain was cancer treatment related other than persistent postsurgical pain (eg, chemotherapy-induced peripheral neuropathy and aromatase inhibitor-induced arthralgia), these patients were included in our study. This is because many breast cancer patients receive (neo) adjuvant therapies, and one-fifth of those who receive taxane-based chemotherapy will develop peripheral neuropathy, 54,58 and about half of women treated with aromatase inhibitors will experience hormonal therapy-induced joint pain. 2 If we excluded these patients, we would be limiting our ability to apply our study results to the general population after breast cancer.…”

Section: Discussionmentioning

confidence: 99%